Proteomics firm Expression Pathology announced this week an agreement with Roche to provide its Liquid Tissue SRM technology in support of the identification of protein biomarkers for cancer drug development.

Under the terms of the agreement, Expression Pathology will develop multiplexed quantitative mass spectrometry assays for the detection of cancer signaling pathway proteins in formalin-fixed, paraffin-embedded tissue samples.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.